Strengthening balance sheet and capitalization is a key Jaguar priority Company continues its sharp, strategic focus on global development program for crofelemer for rare-disease intestinal failure ...

As announced, Jaguar received an up-front payment of $16M of non-dilutive capital in January 2026 upon entering U.S.

As announced, Jaguar received an up-front payment of $16M of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi and Canalevia-CA1 - Jaguar's two comme ...

Dividend intended to provide dilution protection to Jaguar shareholders as company explores pathway to restructure debt ...

Detailed price information for Jaguar Health Inc (JAGX-Q) from The Globe and Mail including charting and trades.

Meaningful non-dilutive capital enables Jaguar to focus on its rare-disease pipeline, which is the subject of ongoing BD discussions with other potential partners As stated above, the agreement also ...

SAN FRANCISCO, CA / ACCESS Newswire / January 6, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that an article published December 29, 2025 in HEALTH, a bi-monthly English and ...

Article discusses results demonstrating parenteral support (PS) reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric patients with intestinal failure ...